Skip to content
mapperlab
← Dashboard
Stock

KIDS

OrthoPediatrics Corp
Latest close $174 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
4
27 funds tracked
Ever held
8
Current + past
New this quarter
0
Exited this quarter
0

Marquee-fund ownership over time

May 17, 2021Feb 14, 2022Nov 14, 2024Feb 17, 2026
Now
4

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Citadel Advisors$25$17-34%
Millennium Management$25$17-32%
Point72 Asset Management re-entered$25$17-32%
D.E. Shaw$17$17+1%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
Two Sigma Investments→ $23-10%
AQR Capital Management→ $23-10%
Bridgewater Associates 2× in & out→ $25-35%
Maverick Capital 2× in & out→ $48-25%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at ORTHOPEDIATRICS CORP. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
11
Filings · last 90d
16
Total on file
256
Recent SEC buffer
Most recent
Jun 10, 2026

30d / 90d windows measured from Jun 10, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 256 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · OrthoPediatrics Corp

Annual figures sourced directly from OrthoPediatrics Corp's 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Revenue
$236.35M
FY2025+15% YoY
Net income
-$39.65M
FY2025-5% YoY
EPS (diluted)
$-1.69
FY2025-3% YoY
Free cash flow(?)
-$15.96M
FY2025+61% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for ORTHOPEDIATRICS CORP — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
Point72 Asset ManagementQ1 2026open$17$18+6%
D.E. ShawQ4 2025open$17$18+9%
Millennium ManagementQ1 2025open$25$18-26%
Point72 Asset ManagementQ1 2025Q4 2025$25$17-32%
Citadel AdvisorsQ3 2024open$25$18-28%
Two Sigma InvestmentsQ3 2024Q2 2025$25$23-10%
AQR Capital ManagementQ3 2024Q4 2024$25$23-10%
Bridgewater AssociatesQ3 2023Q3 2024$39$25-35%
Maverick CapitalQ4 2021Q1 2022$64$48-25%
Bridgewater AssociatesQ3 2021Q1 2023$63$45-29%
Maverick CapitalQ2 2021Q3 2021$54$64+18%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.